Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Vivoryon Therapeutics

DB:PB9
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PB9
DB
€79M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Vivoryon Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer’s disease. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
  • Vivoryon Therapeutics has significant price volatility in the past 3 months.
PB9 Share Price and Events
7 Day Returns
10.2%
DB:PB9
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
14.9%
DB:PB9
-7.4%
DE Biotechs
-14.2%
DE Market
PB9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vivoryon Therapeutics (PB9) 10.2% -15.8% -19.2% 14.9% -77.8% -77.6%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • PB9 outperformed the Biotechs industry which returned -7.4% over the past year.
  • PB9 outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
PB9
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Vivoryon Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vivoryon Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €4.05.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vivoryon Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vivoryon Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PB9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.62
ENXTAM:VVY Share Price ** ENXTAM (2020-04-08) in EUR €3.97
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vivoryon Therapeutics.

DB:PB9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTAM:VVY Share Price ÷ EPS (both in EUR)

= 3.97 ÷ -0.62

-6.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vivoryon Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Vivoryon Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Vivoryon Therapeutics's expected growth come at a high price?
Raw Data
DB:PB9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.37x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vivoryon Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vivoryon Therapeutics's assets?
Raw Data
DB:PB9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €2.14
ENXTAM:VVY Share Price * ENXTAM (2020-04-08) in EUR €3.97
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:PB9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTAM:VVY Share Price ÷ Book Value per Share (both in EUR)

= 3.97 ÷ 2.14

1.86x

* Primary Listing of Vivoryon Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vivoryon Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Vivoryon Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vivoryon Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vivoryon Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vivoryon Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vivoryon Therapeutics expected to grow at an attractive rate?
  • Unable to compare Vivoryon Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vivoryon Therapeutics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Vivoryon Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:PB9 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PB9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PB9 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:PB9 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 -12 -8
2019-09-30 -9 -7
2019-06-30 -6 -7
2019-03-31 -7 -7
2018-12-31 -7 -8
2018-09-30 -8 -8
2018-06-30 -9 -8
2018-03-31 -10 -8
2017-12-31 -12 -8
2017-09-30 -13 -10
2017-06-30 -14 -12
2017-03-31 -14 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vivoryon Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Vivoryon Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PB9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Vivoryon Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PB9 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:PB9 Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.62
2019-09-30 -0.67
2019-06-30 -0.74
2019-03-31 -0.83
2018-12-31 -0.94
2018-09-30 -0.95
2018-06-30 -0.95
2018-03-31 -0.96
2017-12-31 -0.98
2017-09-30 -1.25
2017-06-30 -1.53
2017-03-31 -1.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vivoryon Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Vivoryon Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Vivoryon Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Vivoryon Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Vivoryon Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vivoryon Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vivoryon Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vivoryon Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vivoryon Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Vivoryon Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vivoryon Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Vivoryon Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vivoryon Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PB9 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -7.82 3.02 4.75
2019-09-30 -7.27 2.78 4.44
2019-06-30 -6.71 2.54 4.13
2019-03-31 -7.22 2.71 4.48
2018-12-31 -7.74 2.89 4.84
2018-09-30 -7.78 2.83 4.96
2018-06-30 -7.82 2.76 5.09
2018-03-31 -7.92 2.64 6.27
2017-12-31 -8.01 2.51 7.45
2017-09-30 -10.08 2.71 9.32
2017-06-30 -12.15 2.91 11.18
2017-03-31 -13.02 2.91 11.06
2016-12-31 -13.89 2.91 10.95
2016-09-30 -13.60 2.82 10.65
2016-06-30 -13.32 2.73 10.36
2016-03-31 -13.41 3.01 10.26
2015-12-31 -13.51 3.28 10.16
2015-09-30 -13.69 3.79 9.89
2015-06-30 -13.88 4.23 9.70
2015-03-31 -12.66 3.77 8.85
2014-12-31 -11.44 3.32 8.01
2014-09-30 -10.09 2.65 7.60
2014-06-30 -8.74 2.06 7.10
2014-03-31 -9.25 2.18 7.55
2013-12-31 -9.76 2.30 8.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vivoryon Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vivoryon Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vivoryon Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vivoryon Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vivoryon Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vivoryon Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vivoryon Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vivoryon Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vivoryon Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vivoryon Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Vivoryon Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vivoryon Therapeutics Company Filings, last reported 3 months ago.

DB:PB9 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 42.67 0.00 41.52
2019-09-30 42.67 0.00 41.52
2019-06-30 5.64 0.00 8.00
2019-03-31 5.64 0.00 8.00
2018-12-31 1.23 0.00 3.78
2018-09-30 1.23 0.00 3.78
2018-06-30 4.85 0.00 6.69
2018-03-31 4.85 0.00 6.69
2017-12-31 8.92 0.00 10.29
2017-09-30 8.92 0.00 10.29
2017-06-30 12.21 0.00 14.39
2017-03-31 12.21 0.00 14.39
2016-12-31 16.38 0.00 21.90
2016-09-30 16.38 0.00 21.90
2016-06-30 10.47 0.00 14.25
2016-03-31 10.47 0.00 14.25
2015-12-31 16.13 0.00 21.36
2015-09-30 16.13 0.00 21.36
2015-06-30 10.16 0.00 14.84
2015-03-31 10.16 0.00 14.84
2014-12-31 15.97 0.00 20.92
2014-09-30 15.97 0.00 21.02
2014-06-30 -8.05 9.62 5.93
2014-03-31 -8.05 9.62 5.93
2013-12-31 -4.22 5.35 5.07
  • Vivoryon Therapeutics has no debt.
  • Vivoryon Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vivoryon Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Vivoryon Therapeutics has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of -1.8% each year.
X
Financial health checks
We assess Vivoryon Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vivoryon Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vivoryon Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vivoryon Therapeutics dividends.
If you bought €2,000 of Vivoryon Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vivoryon Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vivoryon Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PB9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PB9 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vivoryon Therapeutics has not reported any payouts.
  • Unable to verify if Vivoryon Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vivoryon Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vivoryon Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vivoryon Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vivoryon Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vivoryon Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vivoryon Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ulrich Dauer
COMPENSATION €222,720
AGE 54
TENURE AS CEO 1.9 years
CEO Bio

Dr. Ulrich Dauer has been Chief Executive Officer and Chairman of the Management Board at Vivoryon Therapeutics AG (formerly, Probiodrug AG) since May 01, 2018. He has been Chief Executive Officer and Managing Director at OMEICOS Therapeutics GmbH since April 13, 2015. Dr. Dauer served as Chief Strategy Officer of Vectura GmbH (alternative name Activaero GmbH). Dr. Dauer co-founded 4SC AG in January 1999 and served as its Chief Executive Officer from 1999 to March 31, 2013 and served as its Chairman of Management Board until March 31, 2013. Prior to that, he served as a Manager at Tripos, where he was responsible for key accounts and the acquisition of new business in Central and Eastern Europe. Before joining TRIPOS GmbH in Munich (Germany), a provider of screening libraries, software and systems integration in the life science business. He is a well-known executive in the healthcare industry as well as in the financial community. Dr. Dauer completed his Doctorate in Chemistry at the Institute of Organic Chemistry, University of Würzburg (Germany).

CEO Compensation
  • Insufficient data for Ulrich to compare compensation growth.
  • Ulrich's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Vivoryon Therapeutics management team in years:

1.9
Average Tenure
56.5
Average Age
  • The average tenure for the Vivoryon Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Ulrich Dauer

TITLE
Chairman of the Management Board & CEO
COMPENSATION
€223K
AGE
54
TENURE
1.9 yrs

Michael Schaeffer

TITLE
Chief Business Officer & Member of the Management Board
COMPENSATION
€222K
TENURE
1.5 yrs

Konrad Glund

TITLE
Co-Founder & Advisor
COMPENSATION
€222K
AGE
66
TENURE
1.9 yrs

Hendrik Liebers

TITLE
COMPENSATION
€319K
AGE
48
TENURE
1.9 yrs

Manuela Bader

TITLE
Director of Investor Relations & Communications

Frank Weber

TITLE
Chief Medical Officer
AGE
59
Board of Directors Tenure

Average tenure and age of the Vivoryon Therapeutics board of directors in years:

9.3
Average Tenure
62.5
Average Age
  • The tenure for the Vivoryon Therapeutics board of directors is about average.
Board of Directors

Erich Platzer

TITLE
Chairperson of the Supervisory Board
AGE
69
TENURE
7.3 yrs

Dinnies von der Osten

TITLE
Vice Chairperson of the Supervisory Board
AGE
58
TENURE
13.3 yrs

Hans-Ulrich Demuth

TITLE
Member of Scientific Advisory Board
AGE
67

Takaomi Saido

TITLE
Member of Scientific Advisory Board

Joerg Neermann

TITLE
Member of the Supervisory Board
AGE
52
TENURE
9.3 yrs

Thomas Bayer

TITLE
Member of Scientific Advisory Board
TENURE
14.6 yrs

Cynthia Lemere

TITLE
Member of Scientific Advisory Board

Charlotte Lohmann

TITLE
Member of the Supervisory Board
AGE
49
TENURE
4.8 yrs

Paul Aisen

TITLE
Member of Clinical Advisory Board

Jeff Cummings

TITLE
Member of Clinical Advisory Board
AGE
69
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Vivoryon Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vivoryon Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Vivoryon Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer’s disease. Its drug candidates target toxic pyroglutamate-Abeta (pGlu-Abeta) through inhibition of Glutaminyl Cyclase (QC), which inhibits the production of pGlu-Abeta; and clearing existing pGlu-Abeta from the brain. The company’s lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIa clinical trials for use in the treatment of Alzheimer’s disease. Its preclinical development products include PBD-C06, a monoclonal antibody to clear the brain from pGlu-Abeta; and PQ1565, a QC-inhibitor. Vivoryon Therapeutics AG has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; and collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease. The company was formerly known as Probiodrug AG and changed its name to Vivoryon Therapeutics AG in June 2019. Vivoryon Therapeutics AG was founded in 1997 and is headquartered in Halle, Germany.

Details
Name: Vivoryon Therapeutics AG
PB9
Exchange: DB
Founded: 1997
€79,302,663
19,975,482
Website: http://www.vivoryon.com
Address: Vivoryon Therapeutics AG
Weinbergweg 22,
Halle,
Saxony-Anhalt, 06120,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTAM VVY Registered Common Shares Euronext Amsterdam NL EUR 27. Oct 2014
OTCPK PRBG.F Registered Common Shares Pink Sheets LLC US USD 27. Oct 2014
DB PB9 Registered Common Shares Deutsche Boerse AG DE EUR 27. Oct 2014
XTRA PB9 Registered Common Shares XETRA Trading Platform DE EUR 27. Oct 2014
LSE 0R3M Registered Common Shares London Stock Exchange GB EUR 27. Oct 2014
BATS-CHIXE VVYA Registered Common Shares BATS 'Chi-X Europe' GB EUR 27. Oct 2014
Number of employees
Current staff
Staff numbers
17
Vivoryon Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:29
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2019/03/28
Last earnings filing: 2020/03/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.